Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
ANAPTYSBIO, INC (ANAB)
Sector: Healthcare; Industry: Biotechnology

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-04 EcoR1 Capital, LLC 10%-Owner, Director Buy 221,500 $23.24 $5,147,444 No
2021-04-27 EcoR1 Capital, LLC 10%-Owner, Director Buy 147,300 $23.63 $3,480,233 No
2021-03-09 EcoR1 Capital, LLC 10%-Owner Buy 3,308,800 $18.93 $62,622,736 No
2021-02-23 EcoR1 Capital, LLC 10%-Owner Buy 29,500 $25.48 $751,657 No
2021-02-12 LOUMEAU ERIC J COO, General Counsel Sell 10,000 $35.00 $350,000 Yes
2019-12-10 Ware J. Anthony Director Buy 3,600 $14.05 $50,580 No
2019-06-10 Suria Hamza President, CEO Sell 22,428 $73.76 $1,654,350 No
2019-06-04 Londei Marco Chief Medical Officer Sell 10,060 $73.06 $734,962 Yes
2019-01-14 Suria Hamza President, CEO Sell 40,000 $70.79 $2,831,532 Yes
2019-01-15 Londei Marco Chief Medical Officer Sell 19,075 $69.88 $1,332,882 Yes
2018-12-17 Londei Marco Chief Medical Officer Sell 30,048 $66.76 $2,005,856 Yes
2018-12-14 Suria Hamza President, CEO Sell 41,728 $69.36 $2,894,375 Yes
2018-12-12 Suria Hamza President, CEO Sell 65,585 $71.47 $4,687,413 Yes
2018-12-03 Piscitelli Dominic Chief Financial Officer Sell 37,000 $72.14 $2,669,158 Yes
2018-04-16 Lydon Nicholas Director Sell 33,000 $86.88 $2,866,913 No
2017-08-21 Novo Holdings A/S 10%-Owner Sell 356,300 $21.10 $7,518,251 No
2017-08-15 Novo Holdings A/S 10%-Owner Sell 178,600 $21.16 $3,778,481 No
2017-08-07 Novo Holdings A/S 10%-Owner Sell 491,294 $21.12 $10,377,406 No
2017-08-03 Novo Holdings A/S 10%-Owner Sell 70,706 $23.31 $1,647,947 No
2017-07-26 Avalon Ventures VII L P See Remarks Sell 37,040 $24.35 $901,924 No
2017-01-31 Novo A/S 10%-Owner Buy 50,000 $15.00 $750,000 Yes
2017-01-31 Topper James N 10%-Owner, Director Buy 400,000 $15.00 $6,000,000 Yes
2017-01-31 Lydon Nicholas Director Buy 16,666 $15.00 $249,990 Yes
2017-01-31 Frazier Healthcare VII, L.P. 10%-Owner Buy 400,000 $15.00 $6,000,000 Yes
2017-01-31 Frazier Healthcare V, LP 10%-Owner Buy 400,000 $15.00 $6,000,000 Yes

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.